PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters

Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death globally, and new immunotherapies developed and under development targeting PD-1/PD-L1 checkpoint inhibition require accurate patient selection to assure good clinical outcome. PD-L1 immunohistochemistry is the current biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Manuel A., Ryall, Karen A., Wilm, Claudia, Caldara, Jenifer, Grote, Hans Juergen, Patterson-Kane, Janet C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991369/
https://www.ncbi.nlm.nih.gov/pubmed/29874226
http://dx.doi.org/10.1371/journal.pone.0196464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991369/
https://www.ncbi.nlm.nih.gov/pubmed/29874226
http://dx.doi.org/10.1371/journal.pone.0196464

Ejemplares similares